Clinical Trial Update: An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass Surgery [Phase 2]

View source ↗

Summary

Phase 2 open-label study assessing XOMA 358 in patients with hypoglycemia after gastric bypass surgery has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoglycemia After Gastric Bypass Surgery

Drugs mentioned

• XOMA 358

Snippet

Sponsor: XOMA (US) LLC | Conditions: Hypoglycemia | Phase 2 | Status: COMPLETED